Wednesday, July 6, 2022 Daily Archives

A Flexible Intensified Seed Train to Boost Biopharma Productivity

This webcast features: Yuliya Mikhed, PhD, Product Manager, Biostat® RM Bioreactors & Matthew Houser, Product Manager, Biostat STR®, Sartorius. Biopharma manufacturers need adaptable, efficient facilities that support varied products and production demands. Process intensification (PI) and perfusion processes can help meet these challenges. In this webinar, Sartorius experts present the latest PI technologies, including advanced Biostat® bioreactors integrated with PAT functionality controlled by the Biobrain® automation platform. Key Takeaways: Discover Biostat® RM, Biostat® STR, and Biobrain® automation. Explore the flexible…

Wacker breaks ground on $102m mRNA site in Germany

Once the expansion is complete the manufacturing capacity in Halle, Germany will be more than tripled, says Wacker. The expansion, which sees contract development manufacturing organization (CDMO) Wacker invest over $102 million, will consist of four floors connected to an existing building. In addition to the four messenger RNA (mRNA) production lines, the building will also include quality control laboratories, storage areas, and office space. According to Wacker, once operational the plant will produce mRNA coronavirus vaccines. In April the…

AstraZeneca forks out $100m to acquire TeneoTwo

AstraZeneca says it will bolster its hematology pipeline through the acquisition of TeneoTwo and its clinical-stage T-cell engager, TNB-486. A significant part of the deal, which will see AstraZeneca make an upfront payment of $100 million and additional milestone related payments up to $1.7 billion, is the acquisition of TeneoTwo’s Phase I clinical-stage CD19/CD4 T-cell engager, TNB-486. TNB-486 is an experimental drug that aims to treat relapsed and refractory B-cell non-Hodgkin lymphoma. T-cell engagers work by redirecting the immune systems…

Pfizer licenses plasmid DNA-alternative tech from Touchlight

Touchlight will license its patented doggybone DNA (dbDNA) technology to Pfizer for the manufacture of mRNA therapeutics, vaccines, and gene therapies. The agreement will provide Pfizer with access to Touchlight’s dbDNA patent rights, which the firm said will allow it to rapidly produce DNA templates as starting materials for messenger RNA (mRNA)-based vaccines and other therapeutics. “dbDNA is a minimal, linear, covalently closed DNA vector that contains no bacterial sequences such as antibiotic resistance genes or origins of replication,” a…